Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018488 | 1.00 | MEN1 (0.44) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL31018491 | 1.00 | MEN1 (0.44) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL31018502 | 1.00 | MEN1 (0.44) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL4138679 | 0.78 | MTNR1A (0.48) | — | |
| SCHEMBL4551372 | 0.78 | TACR2 (0.40) | — | |
| SCHEMBL7681443 | 0.78 | CREBBP (0.45) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL7488882 | 0.76 | GAA (0.44) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL4817473 | 0.73 | KDM4E (0.45) | — | |
| SCHEMBL28923974 | 0.72 | GRIN2B (0.44) | — | |
| SCHEMBL6633357 | 0.71 | ALDH1A1 (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-10-01 | — | — | US | disclosed |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2020-08-06 | — | — | US | disclosed |
| WO-2019012149-A1 | THERAPEUTIC MODULATORS OF THE REVERSE MODE OF ATP SYNTHASE | FORREST MICHAEL DAVID (GB) | 2019-01-17 | — | — | WO | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-0892797-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306253-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | ATP5ME, ATP5F1A, ATP5MG | MEN1 2378/4885KMT2A 2520/4885CYP3A4 1559/4885 |
| US-20200247758-A1 | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase | ATP5ME, ATP5MG, ATP5F1A | MEN1 1843/4885KMT2A 2190/4885CYP3A4 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.